





All-Wales consensus guideline on the initial management of Bi-specific related Cytokine Release Syndrome (CRS)

Withhold bispecific until resolution of symptoms and follow local disease specific ongoing management

American Society for Transplantation and Cellular therapy (ASTCT) grading



| | Fever $\geq 38^{\circ}\text{C}$ | Low blood pressure | Hypoxia | Treatment | ICU |
|---------|---------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------|-------------------|
| Grade 1 | Present | Absent | Absent | Consider Dexamethasone IV 10mg QDS and Tocilizumab | Not necessary |
| Grade 2 | Present | Present – does not require vasopressors | If present, only requires O_2 supplement ≤ 6 l/min | Give Dexamethasone IV 10mg QDS and Tocilizumab | Alert ICU |
| Grade 3 | Present | Present – requires 1 vasopressors | If present, requires O_2 supplement > 6 l/min | Give Dexamethasone IV 10mg QDS and Tocilizumab | Management in ICU |
| Grade 4 | Present | Present – requires ≥ 2 vasopressors (excluding vasopressin) | If present, requires positive pressure (CPAP, BPAP, mechanical ventilation) | Give Dexamethasone IV 10mg QDS and Tocilizumab | Management in ICU |

Tocilizumab IV 8 mg/kg (max 800 mg/dose)

Yanez L, et al. ESMO Open 2020;4:e000746 2.